Consensus Bio-Rad Laboratories, Inc.

Stocks

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 07:00:02 28/10/26 am AEDT			5-day change	1st Jan Change
380.99 ^USD	+2.30%		+7.47%	+25.74%

25/09	Bio-Rad Laboratories, Inc. Presents at Bernstein Insights: Healthcare Leaders and Disruptors ? 3rd Annual Healthcare Forum, Sep-24-2026 08:50 AM
10/09	Bio-Rad Laboratories, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 03:45 PM

Evolution of the Average Target: Bio-Rad Laboratories, Inc.

Evolution of the Target Price: Bio-Rad Laboratories, Inc.

Changes in Analyst Recommendations: Bio-Rad Laboratories, Inc.

be15d2d7b1b0553a125df32.dpAfif_l_aIBjxiT4KUxJ0iXIZqv0507r6ngyQR27gQ.RtRG89KopMFgwW7KsM1mUTvIEOv4lvVK3pvNoF4dmmk40VW8jtGqzm_Efw~67888a3e8997864e237fe70cfa5d59b4

Analysts' recommendations: Bio-Rad Laboratories, Inc.

07/08	RBC Adjusts PT on Bio-Rad Laboratories to $390 From $370, Maintains Outperform Rating	MT
05/08	RBC Adjusts Price Target on Bio-Rad Laboratories to $370 From $320, Maintains Outperform Rating	MT
16/05	Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says	MT
07/04	Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $300 From $375	MT
14/02	UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating	MT
30/10/25	Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair…
03/09/25	RBC Raises Price Target on Bio-Rad Laboratories to $437 From $409, Keeps Outperform Rating	MT
01/08/25	UBS Adjusts Price Target on Bio-Rad Laboratories to $325 From $310, Maintains Buy Rating	MT
01/08/25	RBC Raises Price Target on Bio-Rad Laboratories to $409 From $387, Keeps Outperform Rating	MT
01/07/25	RBC Raises Price Target on Bio-Rad Laboratories to $387 From $381, Keeps Outperform Rating	MT
02/05/25	UBS Adjusts Price Target on Bio-Rad Laboratories to $310 From $355, Maintains Buy Rating	MT
02/05/25	RBC Cuts Price Target on Bio-Rad Laboratories to $392 From $409, Keeps Outperform Rating	MT
08/04/25	RBC Cuts Price Target on Bio-Rad Laboratories to $409 From $430, Keeps Outperform Rating	MT
15/02/25	UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating	MT
14/02/25	RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating	MT
04/02/25	RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating	MT
09/12/24	RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating	MT
01/11/24	UBS Adjusts Price Target on Bio-Rad Laboratories to $390 From $400, Maintains Buy Rating	MT
01/10/24	Citigroup Upgrades Bio-Rad Laboratories to Buy From Neutral, Adjusts Price Target to $400 From $350	MT
13/09/24	RBC Raises Price Target on Bio-Rad Laboratories to $446 From $401, Keeps Outperform Rating	MT
28/08/24	Wells Fargo Initiates Bio-Rad Laboratories at Equalweight With $340 Price Target	MT
03/08/24	Citigroup Adjusts Price Target on Bio-Rad Laboratories to $350 From $300	MT
03/08/24	UBS Adjusts Price Target on Bio-Rad Laboratories to $400 From $385, Maintains Buy Rating	MT
02/08/24	RBC Trims Price Target on Bio-Rad Laboratories to $401 From $402, Keeps Outperform Rating	MT
24/06/24	RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
BIO-RAD LABORATORIES, INC.	-	-12.07%
ABBOTT LABORATORIES		+14.96%
STRYKER CORPORATION		+20.3%
MEDTRONIC PLC		+11.35%
ESSILORLUXOTTICA		+18.76%
CENCORA, INC.		+13.44%
HOYA CORPORATION		+16.14%
BECTON, DICKINSON AND COMPANY		+0.28%
IDEXX LABORATORIES, INC.		+23.73%
ALCON INC.		+30.6%
Average		+13.75%
Weighted average by Cap.		+15.47%